3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study

      research-article
      1 , 1 , 1 , 4 , 1 , 1 , 2 , 3 , 1 , 1
      (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab), (Collab)
      Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
      Oxford University Press
      HIV, biomarkers, cognitive impairment

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Changes in Veterans Aging Cohort Study (VACS) Index scores correspond to changes in neurocognitive function among human immunodeficiency virus-infected persons, with higher VACS Index scores conferring a notable increased risk for neurocognitive decline and incident impairment.

          Abstract

          Background.  The Veterans Aging Cohort Study (VACS) Index, a composite marker of disease severity among human immunodeficiency virus (HIV)–infected persons, has been associated with concurrent risk for neurocognitive impairment (NCI). The present study examined whether the VACS Index predicts longitudinal neurocognitive change.

          Methods.  Participants included 655 HIV-infected persons followed for up to 6 years in cohort studies at the University of California, San Diego, HIV Neurobehavioral Research Program (mean age at baseline, 42.5 years; 83% male; 60% white; AIDS in 67%; median current CD4 + T-cell count, 346/μL; 61% receiving antiretroviral therapy). The VACS Index was calculated through standard methods. Participants completed a comprehensive neurocognitive battery. Neurocognitive status was plotted over time using demographically and practice-adjusted global and domain T scores. NCI was defined by global deficit scores derived from T scores.

          Results.  Baseline VACS Index scores were not predictive of changes in global T scores during the follow-up period ( P = .14). However, in time-dependent analyses adjusting for covariates, higher VACS Index scores were significantly associated with worse global and domain neurocognitive performance ( Ps < .01), as well as increased risk for developing NCI in a subgroup of persons who were neurocognitively normal at baseline (hazard ratio [HR], 1.17; P < .001). We categorized VACS Index scores by quartiles and found that the upper-quartile group was significantly more likely to develop NCI than the lower quartile (HR, 2.16; P < .01) and middle groups (HR, 1.76; P < .01).

          Conclusions.  Changes in VACS Index scores correspond to changes in neurocognitive function. HIV-infected persons with high VACS Index scores are at increased risk for decline and incident NCI. The VACS Index shows promise as a tool for identifying HIV-infected persons at risk for NCI.

          Related collections

          Author and article information

          Journal
          Clin Infect Dis
          Clin. Infect. Dis
          cid
          cid
          Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
          Oxford University Press
          1058-4838
          1537-6591
          01 September 2016
          19 May 2016
          : 63
          : 5
          : 694-702
          Affiliations
          [1 ] Department of Psychiatry
          [2 ] Department of Neurosciences
          [3 ] Department of Medicine, University of California , San Diego
          [4 ] Psychology Department, University of Alabama, Birmingham
          Author notes
          Correspondence: M. J. Marquine, University of California San Diego, HIV Neurobehavioral Research Program, 220 Dickinson St, Ste B (8231), San Diego, CA 92103 ( mmarquine@ 123456ucsd.edu ).
          Article
          PMC4981756 PMC4981756 4981756 ciw328
          10.1093/cid/ciw328
          4981756
          27199461
          c4dff1bf-dc70-4595-b846-b94dfad7be9a
          © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
          History
          : 15 January 2016
          : 7 May 2016
          Funding
          Funded by: National Institutes of Health;
          Award ID: P30MH062512
          Award ID: U01MH083506
          Award ID: R24MH59745
          Award ID: P01DA12065
          Award ID: K99AG048762
          Award ID: T32MH019934
          Award ID: K23MH105297
          Categories
          HIV/AIDS

          HIV,biomarkers,cognitive impairment
          HIV, biomarkers, cognitive impairment

          Comments

          Comment on this article